1531589-13-5
1531589-13-5
Chemical Structure
Brolucizumab
Synonym(s): DLX1008; ESBA 1008; RTH258
- CAS No.: 1531589-13-5
- Formula:N/A
- Molecular Weight:(26.18 kDa)
SMILES: [Brolucizumab]
Biological Activity: Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab can be used for the research of cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Brolucizumab | 99.90% | Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab can be used for the research of cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Szabó E, et, al. Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models. J Pharmacol Exp Ther. 2018 May;365(2):422-429. [Content Brief]
- [2]. Eason AB, et, al. DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma. PLoS One. 2020 May 14;15(5):e0233116. [Content Brief]
Keywords
